TARGETED ANTI-INFLAMMATORY THERAPEUTICS BIOMARKER-SUPPORTED APPROACHES TO ADDRESS UNMET NEEDS Exalys Therapeutics is developing a portfolio of novel anti-inflammatory therapeutics with best-in-class properties to target a range of diseases with urgent unmet needs and limited treatment options. Exalys is initially targeting postoperative delirium, the most common complication of surgery in olderContinue reading
Investors 2
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | Catalys Pa... | catalyspac... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 28.07.2020 | Exalys Therapeutics has raised a $15M Series A to commercial... | - | connect.or... |
| 16.07.2020 | Domain Associates and Catalys Pacific Launch Exalys Therapeu... | The new company is focused on the development of first-in-class therapies for the treatment of infla... | catalyspac... |